Steris PLC
STE
255.76
+1.00
+0.39%
Steris PLC
US · STE
#909 by market cap
Listed 1970
255.76
+1.00
+0.39%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 101.46% -0.10pp
- Institutions
- 1,029 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund86.97%
Hedge Fund6.76%
Public Company2.69%
Government Pension Fund1.50%
Private Company1.48%
Sovereign Wealth Fund1.27%
Individual/Insider0.33%
Insurance Company0.29%
Family Office/Trust0.26%
Top holders as of 2026-09-30
BlackRock
10.12% · 9.83M sh
Vanguard Capital Management, LLC
7.14% · 6.93M sh
State Street Global Advisors
5.34% · 5.18M sh
Vanguard Portfolio Management, LLC
5.10% · 4.95M sh
MFS Investment Management
3.93% · 3.81M sh
Wellington Management Group
3.53% · 3.43M sh
Orbis Investment Management Limited
3.16% · 3.07M sh
Geode Capital Management, LLC
2.73% · 2.65M sh
Morgan Stanley Investment Management Inc.
2.29% · 2.22M sh
Mitsubishi UFJ Asset Management
2.24% · 2.18M sh
Generation Investment Management LLP
2.34% · 2.28M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Carestio | Chief Executive Officer | 0.07% |
| Michael Tokich | Former Senior Vice President | 0.05% |
| Richard Breeden | Former Independent Director | 0.04% |
| John Zangerle | Senior Vice President | 0.04% |
| Jacqueline Kosecoff | Former Independent Director | 0.03% |
| Mohsen Sohi | Independent Chairperson | 0.03% |
| Cary Majors | Senior VP & President of Healthcare | 0.02% |
| Mary Fraser | SVP & Chief Human Resources Officer | 0.01% |
| Karen Burton | Senior VP, CFO & Chief Accounting Officer | 0.01% |
| Julia Madsen | Senior VP & GM of Life Sciences | 0.01% |
| Kenneth Kohler | Senior VP & GM of AST | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-12 | Julia Madsen | Senior VP & GM of Life Sciences | Intent to Sell (Form 144) | -2,046 | $260.00 |
| 2026-11-10 | Karen Burton | Senior VP, CFO & Chief Accounting Officer | Derivative Exercise and Sale | -5,880 | $147.05–255.62 |
| 2026-11-09 | Mohsen Sohi | Independent Chairperson | Derivative Exercise and Sale | -4,893 | $114.74–253.90 |
| 2026-09-30 | Karen Burton | Senior VP, CFO & Chief Accounting Officer | Sale to Issuer | -228 | -- |
| 2026-08-17 | Richard Breeden | Former Independent Director | Intent to Sell (Form 144) | -4,110 | $231.90 |
| 2026-08-11 | Mohsen Sohi | Independent Chairperson | Derivative Exercise and Sale | -4,058 | $86.23–235.78 |
| 2026-08-09 | Mohsen Sohi | Independent Chairperson | Other Derivative Acquisition | +1,099 | $238.91 |
| 2026-08-09 | Mohsen Sohi | Independent Chairperson | Other Derivative Acquisition | +1,229 | -- |
| 2026-08-09 | Cynthia Feldmann | Independent Director | Other Derivative Acquisition | +512 | -- |
| 2026-08-09 | Cynthia Feldmann | Independent Director | Other Derivative Acquisition | +1,506 | $238.91 |
| 2026-08-09 | Paul Martin | Independent Director | Other Derivative Acquisition | +512 | -- |
| 2026-08-09 | Paul Martin | Independent Director | Other Derivative Acquisition | +1,506 | $238.91 |
| 2026-08-09 | Nirav Shah | Independent Director | Other Derivative Acquisition | +512 | -- |
| 2026-08-09 | Nirav Shah | Independent Director | Other Derivative Acquisition | +1,506 | $238.91 |
| 2026-08-09 | Louis Shapiro | Independent Director | Other Derivative Acquisition | +1,025 | -- |
| 2026-08-09 | Christopher Holland | Independent Director | Other Derivative Acquisition | +1,025 | -- |
| 2026-08-09 | Pierre Boulud | Independent Director | Other Derivative Acquisition | +1,025 | -- |
| 2026-08-09 | Esther Alegria | Independent Director | Other Derivative Acquisition | +512 | -- |
| 2026-08-09 | Esther Alegria | Independent Director | Other Derivative Acquisition | +1,506 | $238.91 |
| 2026-06-30 | Mohsen Sohi | Independent Chairperson | Derivative Exercise and Sale | -1,837 | $71.40–212.30 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:07 · For reference only, not investment advice and not tailored to your situation.
Steris PLC discussion 0 comments